Burberry no longer in talks with Interparfums
Burberry, the iconic British luxury brand, announced on Friday that discussions with Interparfums regarding the possible termination of their licence agreement have ended.
Burberry, the iconic British luxury brand, announced on Friday that discussions with Interparfums regarding the possible termination of their licence agreement have ended.
Interparfums is currently the exclusive worldwide licensee for Burberry fragrance and beauty products.
The firm announced on July 17th that it was talking with the global fragrance company about ending their near 20-year licence agreement by exercising its option to buy out for €181m.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Burberry said that it wanted to establish a "new operating model" for the fragrance business and the move would be an attempt to "maintain flexibility in pursuing its objective to develop fully this business in the future."
Nevertheless, Burberry revealed on Friday that it is no longer in talks with Interparfums: "Burberry continues to pursue various strategic options to develop fully its fragrance and beauty business in the future," the company said in a statement.
BC
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Trump wants to colonise Mars – will it happen?
Donald Trump wants to plant the US flag on Mars. Could humans really live there?
By Simon Wilson
-
Klarna postpones US IPO as Trump's tariffs rattle markets
Buy-now-pay-later lender Klarna has postponed its US initial public offering owing to the market turbulence. It is not alone, says Matthew Partridge
By Dr Matthew Partridge